NZ593392A - Biomarker for detecting bladder cancer - Google Patents

Biomarker for detecting bladder cancer

Info

Publication number
NZ593392A
NZ593392A NZ593392A NZ59339209A NZ593392A NZ 593392 A NZ593392 A NZ 593392A NZ 593392 A NZ593392 A NZ 593392A NZ 59339209 A NZ59339209 A NZ 59339209A NZ 593392 A NZ593392 A NZ 593392A
Authority
NZ
New Zealand
Prior art keywords
bladder cancer
specific biomarker
patient
amount
cancer
Prior art date
Application number
NZ593392A
Other languages
English (en)
Inventor
Richard Morgan
Hardev S Pandha
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of NZ593392A publication Critical patent/NZ593392A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ593392A 2008-12-23 2009-12-21 Biomarker for detecting bladder cancer NZ593392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0823445.2A GB0823445D0 (en) 2008-12-23 2008-12-23 Biomarker
PCT/GB2009/002926 WO2010073001A1 (en) 2008-12-23 2009-12-21 Biomarker

Publications (1)

Publication Number Publication Date
NZ593392A true NZ593392A (en) 2013-05-31

Family

ID=40344114

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593392A NZ593392A (en) 2008-12-23 2009-12-21 Biomarker for detecting bladder cancer

Country Status (15)

Country Link
US (1) US9624548B2 (enExample)
EP (1) EP2382327B1 (enExample)
JP (1) JP5947040B2 (enExample)
CN (1) CN102301006B (enExample)
AU (1) AU2009332712B2 (enExample)
BR (1) BRPI0923525A2 (enExample)
CA (1) CA2747760C (enExample)
ES (1) ES2725150T3 (enExample)
GB (1) GB0823445D0 (enExample)
IL (1) IL213510A (enExample)
MX (1) MX343251B (enExample)
NZ (1) NZ593392A (enExample)
RU (1) RU2573925C2 (enExample)
WO (1) WO2010073001A1 (enExample)
ZA (1) ZA201105184B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
US11371941B2 (en) * 2016-07-04 2022-06-28 Celltool Gmbh Device and method for the determination of transfection
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
EP4043583A4 (en) 2019-10-02 2023-11-08 Kyushu University, National University Corporation Biomarker, method, kit and array for predicting therapeutic effects of bcg intravesical infusion therapy in treating bladder cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469089A1 (en) 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
ES2384071T3 (es) * 2007-01-19 2012-06-29 Epigenomics Ag Métodos y ácidos nucleicos para análisis de trastornos proliferativos celulares
JP5694776B2 (ja) 2007-12-11 2015-04-01 エピゲノミクス アーゲー 細胞増殖性障害の解析のための方法及び核酸

Also Published As

Publication number Publication date
CA2747760A1 (en) 2010-07-01
MX2011006773A (es) 2011-08-03
US20120020888A1 (en) 2012-01-26
CA2747760C (en) 2020-01-21
IL213510A0 (en) 2011-07-31
ES2725150T3 (es) 2019-09-19
CN102301006B (zh) 2015-07-15
AU2009332712B2 (en) 2015-05-28
ZA201105184B (en) 2012-02-29
US9624548B2 (en) 2017-04-18
AU2009332712A1 (en) 2011-07-07
GB0823445D0 (en) 2009-01-28
JP5947040B2 (ja) 2016-07-06
JP2012513584A (ja) 2012-06-14
WO2010073001A1 (en) 2010-07-01
EP2382327B1 (en) 2019-02-13
MX343251B (es) 2016-10-31
CN102301006A (zh) 2011-12-28
RU2573925C2 (ru) 2016-01-27
BRPI0923525A2 (pt) 2020-08-11
IL213510A (en) 2016-04-21
EP2382327A1 (en) 2011-11-02
RU2011130795A (ru) 2013-01-27

Similar Documents

Publication Publication Date Title
WO2007117444A3 (en) Protein detection by aptamers
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
NZ593392A (en) Biomarker for detecting bladder cancer
ZA200805787B (en) Detection of cancer by elevated levels of BCL-2
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
MX337991B (es) Metodo para detectar cancer.
JP2008249727A5 (enExample)
GB201300533D0 (en) Methods of monitoring conditions by sequence analysis
JP2009504142A5 (enExample)
SG134283A1 (en) Biomarkers for liver fibrotic injury
NZ586737A (en) Compositions and methods of detecting tiabs
MY145455A (en) Diagnostic biomolecule(s)
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
WO2006010047A3 (en) Methods and compositions for the detection of ovarian cancer
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
US20170321277A1 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
WO2013010181A3 (en) Methods of diagnosing cancer using epigenetic biomarkers
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009141352A3 (en) Risk analysis in patients with and without metabolic syndrome
WO2014062069A4 (en) Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
WO2007127461A3 (en) Composition and methods for the detection of cripto-3
WO2010142651A3 (en) Method for determining the risk of developing brain metastasis, and a kit to carry out said method
GB0802456D0 (en) Diagnostic method

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2016 BY LEA SKYLLERSTEDT

Effective date: 20131231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2017 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20161215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2018 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20171215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2019 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20181213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY DR. STEFFEN SCHWARZ

Effective date: 20191217

LAPS Patent lapsed